Grupo para la caracterización molecular de las neoplasias hematológicas
University of Calgary
Calgary, CanadáPublicaciones en colaboración con investigadores/as de University of Calgary (8)
2023
-
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031
2022
-
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
Blood, Vol. 140, Núm. 8, pp. 839-850
2020
2018
-
Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia
New England Journal of Medicine, Vol. 378, Núm. 12, pp. 1107-1120
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2015
-
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Haematologica, Vol. 100, Núm. 10, pp. 1327-1333
-
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma
Haematologica, Vol. 100, Núm. 10, pp. 1334-1339
2014
-
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
New England Journal of Medicine, Vol. 370, Núm. 12, pp. 1101-1110